Case study

16 Dec 2020

Dry Eye Disease Case Study


A rapidly growing, biopharmaceutical company, dedicated to developing innovative therapies and novel biologics for rare and underserved ocular disorders, aggressively pursues new treatments for ocular surface diseases, retinal diseases as well as a gene therapy pipeline.

  • Study Phase: III
  • Indication: Dry Eye Disease
  • Sites: 25
  • Services: Full Service


  • To initiate 25 sites in the US within 4 weeks
  • To randomize 250 patients within 6 weeks
  • To clean all data within 1 week of Last Patient Out
  • To deliver Top Line Results within 3 weeks of Last Patient Out

See Other Case Studies

TFS involved in European global customer’s pre-lau...

TFS was requested to prepare and conduct a Late Phase global proposal to support the pre-launch activities of two pro...

Read more

How TFS Strategic Resourcing Solutions deployed a ...

Given the catastrophic spread of COVID-19, the search for safe and effective therapies has taken on an unpreced...

Read more

TFS & a Global Biotech Company

As clinical trials grow increasingly complex, timelines shorten, and R&D costs soar. Today’s biopharmaceuti...

Read more